PDGFRA and gastrointestinal stromal tumor: Recently, novel TKIs, such as ripretinib and avapritinib, have been evaluated and approved for refractory advanced GIST or PDGFRA exon 18-mutated GIST patients by FDA in May 2020 and January 2020, respectively, based on the results of randomized phase III trials [35, 38].